We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Advanced Anesthesia Technology to Precisely Control Unconsciousness Could Reduce Postoperative Side Effects

By HospiMedica International staff writers
Posted on 01 Nov 2023
Print article
Image: The new anesthesia technology precisely controlled unconsciousness in animal tests (Photo courtesy of 123RF)
Image: The new anesthesia technology precisely controlled unconsciousness in animal tests (Photo courtesy of 123RF)

Anesthesiologists could achieve better results with less medication if they had a precise method for managing dosages. This would enable them to maintain the perfect level of unconsciousness while minimizing post-surgery cognitive issues, particularly in vulnerable populations like older adults. However, given their multitude of tasks, such as keeping patients both stable and deeply unconscious, anesthesiologists can't accomplish this without technological help. To tackle this challenge, scientists have created a closed-loop system that uses brain state monitoring to automatically adjust the doses of the anesthesia drug propofol at 20-second intervals.

The advanced closed-loop anesthesia delivery (CLAD) system developed by researchers at MIT (Cambridge, MA, USA) and Massachusetts General Hospital (Boston, MA, USA) tailors propofol dosages by monitoring the brain state of the individual, with the objective of achieving the specific level of unconsciousness required while reducing postoperative side effects. The CLAD system employs real-time feedback from brain state metrics to continuously adjust the administered dose.

The uniqueness of the CLAD system lies in its use of direct, physiologically based brain state indicators to measure unconsciousness. In the operating room, anesthesiologists usually depend on indirect signs like heart rate, blood pressure, and physical immobility. Instead, this research team established a brain-based indicator by recording shifts in neural spiking activity during unconscious states, along with the larger scale rhythms they generate, known as Local Field Potentials (LFPs). By correlating LFP power with these spiking-based measures in animal subjects, they identified that the total LFP power between 20 and 30 Hz serves as a reliable unconsciousness marker.

Additionally, the researchers integrated a physiologically principled model into the system that determines the pharmacokinetics (PK) and pharmacodynamics (PD) of propofol into their system. The model helps to determine both the speed and dosage of the drug needed to change the state of consciousness. The system adjusts the infusion rate every 20 seconds based on the difference between the measured LFP power and the targeted level set by the anesthesiologist, using this PK/PD model to close the gap. Initially, the team conducted computer simulations of the CLAD system under real-world conditions. Then, they carried out nine experiments, each lasting 125 minutes, with two animal subjects. In each case, the system had to maintain the animals at a specific unconsciousness level for various durations. It successfully kept the unconsciousness marker extremely close to the targeted levels during the entire experiment.

However, the researchers admit that more work is required to make the system suitable for human application. One necessary step is shifting the system's foundation to EEGs, which can be measured non-invasively from the scalp. Alongside this, a reliable marker for unconsciousness based on human EEGs must be identified. Additionally, they aim to enhance the system to not only sustain unconsciousness but also to help initiate it and aid in bringing the patient back to consciousness.

“One of the ways to improve anesthesia care is to give just the right amount of drug that’s needed,” said Emery N. Brown, Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience at MIT and an anesthesiologist at MGH. “This opens up the opportunity to do that in a really controlled way.”

Related Links:
MIT 
Massachusetts General Hospital 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Mobile Fetal Monitor
FTS-6 Mobile
New
Digital Brain Electric Activity Mapping Device
KT88

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.